SB106 would expand Kentucky’s abortion-related restrictions by defining key terms such as “abortifacient,” “pregnant,” “fertilization,” and “unborn human being,” and by prohibiting the knowing administration, prescription, mailing, sale, or use of drugs, substances, instruments, or procedures with the specific intent to cause or abet the termination of an unborn human being. The bill also creates a separate category for “foreign senders,” defined broadly to include out-of-state or otherwise external actors who mail, prescribe, or place abortifacients into commerce with knowledge they may be used in Kentucky.
The bill is structured to take effect only if the U.S. Supreme Court reverses Roe v. Wade in whole or in part, or if a constitutional amendment restores Kentucky’s authority to prohibit abortion. It includes exceptions for licensed physicians acting in reasonable medical judgment to prevent death or serious permanent impairment to the pregnant woman, and for accidental or unintentional injury or death to the unborn human being during medical treatment. It also states that the pregnant woman herself cannot be criminally prosecuted under the section, and it preserves the use of contraceptives administered before pregnancy can be medically determined.
SB106 would impose criminal penalties on violators, making most violations a Class D felony and violations by foreign senders a Class C felony with possible imprisonment and fines up to $100,000. It also creates a private civil right of action allowing a pregnant woman who receives an abortifacient to sue a person or entity that knowingly or intentionally violates the section, with available remedies including injunctive relief, $10,000 per abortion, and attorney’s fees and costs. The bill further addresses Medicaid funding by tying its provisions to federal requirements governing when states must fund abortion to remain eligible for Medicaid funds.
The bill would also amend Kentucky controlled-substances law so that the Cabinet for Health and Family Services must place a substance in Schedule IV if it is an abortifacient as defined in the bill or an abortion-inducing drug under existing law. This would affect how certain drugs are classified and regulated in the state, potentially increasing restrictions on access, prescribing, and distribution.
No committee discussion or recorded votes were provided, so the overall sentiment cannot be measured from the legislative record included here. Based on the bill text, the measure is strongly anti-abortion and designed to expand enforcement tools, while likely drawing opposition from abortion-rights advocates, medical providers concerned about criminal liability, and critics of the private-enforcement and foreign-sender provisions.
SB106 would amend Kentucky law to create a broader statutory framework for abortion prohibition and enforcement, including new definitions, criminal penalties, civil remedies, and drug-scheduling consequences. It would directly affect KRS 311.772 and KRS 218A.100, and could expose physicians, prescribers, distributors, and out-of-state actors to criminal and civil liability if they knowingly participate in abortion-related conduct as defined by the bill. It also preserves limited medical exceptions and expressly shields pregnant women from criminal punishment under the section.
No voting history or committee transcript was provided, so there is no recorded legislative debate to summarize. From the text alone, SB106 appears to reflect a strongly pro-life policy position and a desire to prepare Kentucky law for a post-Roe legal environment. The bill’s structure suggests support from abortion opponents and likely concern or opposition from abortion-rights advocates, healthcare providers, and civil-liberties critics.
The main points of contention are likely to be the bill’s broad definitions of abortifacient and foreign sender, the criminal penalties for providers and distributors, and the private right of action that allows civil suits with statutory damages and attorney’s fees. Another likely dispute is the medical-exception language, which permits treatment only when necessary to prevent death or serious permanent impairment, a standard some may view as too narrow or uncertain in practice. Critics may also object to the bill’s attempt to regulate drugs through scheduling and to its interaction with federal Medicaid funding rules.